| HOME >> MEDICINE >> TECHNOLOGY |
883,617773,9942,482,7902,338,574Inventory reserve
------576,021Loss on sale of patents
824,241--824,241--Severance and other related expense
----349,9801,120,0006,568,1324,690,47717,867,02716,053,538Operating loss
(3,139,449)(1,834,088)(9,843,483)(7,636,334)Other income (expense):Loss on change in fair value of embedded conversion feature
------(8,125,000)Debt issuance cost
------(2,007,534)Interest and other income
11,05231,55162,10651,123Interest expense
(2,861,773)(2,621,071)(8,395,849)(6,739,557)(Loss) gain from investment in former China joint venture
--40,051(1,375,926)123,881Loss from investment in Tarsa
(1,301,143)--(2,819,143)--Loss before income taxes
(7,291,313)(4,383,557)(22,372,295)(24,333,421)Income tax benefit from sale of state tax benefit
------359,357Net loss
$ (7,291,313)$(4,383,557)$ (22,372,295)$(23,974,064)Loss per share – basic and diluted:Net loss per share
$ (0.08)$(0.05)$ (0.24)$(0.26)Weighted average number of shares outstanding -basic and diluted
92,910,23892,085,58492,636,69291,895,038
'/>"/>
| SOURCE Unigene Laboratories, Inc. Copyright©2010 PR Newswire. All rights reserved |